(Q68529097)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

title

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

author name string

J Bladé

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

A Alcalá

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

J Maldonado

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

J García-Conde

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

M J Moro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

M A Sanz Sanz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

C Alonso

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

A Zubizarreta

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

C Besses

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

publication date

1 June 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

page(s)

319-322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence Data

25 September 2019

cites work

1 reference

12 December 2020

Rationale for the use of alternating non-cross-resistant chemotherapy.

1 reference

12 December 2020

Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma

1 reference

12 December 2020

Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.

1 reference

12 December 2020

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

12 December 2020

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

12 December 2020

Chemotherapy for multiple myeloma

1 reference

12 December 2020

Indication for therapy in multiple myeloma: should it be stage or stability?

1 reference

12 December 2020

Treatment of multiple myeloma: a randomized study of three different regimens

1 reference

12 December 2020

The survival time of patients with plasmocytic myeloma

1 reference

12 December 2020

Results of the MRC myelomatosis trials for patients entered since 1980

1 reference

12 December 2020

Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB

1 reference

12 December 2020

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study

1 reference

12 December 2020

Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients

1 reference

12 December 2020

Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma

1 reference

12 December 2020

Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study

1 reference

12 December 2020

An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study

1 reference

12 December 2020

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

1 reference

12 December 2020

Progress in the treatment of plasma cell myeloma?

1 reference

12 December 2020

Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy

1 reference

12 December 2020

Duration of survival in multiple myeloma

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01737844

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2198075%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

1 reference